Personal CFO Solutions LLC Sells 1,747 Shares of Medtronic PLC $MDT

Personal CFO Solutions LLC lessened its stake in shares of Medtronic PLC (NYSE:MDT) by 15.0% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 9,867 shares of the medical technology company’s stock after selling 1,747 shares during the period. Personal CFO Solutions LLC’s holdings in Medtronic were worth $860,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MDT. Brighton Jones LLC boosted its stake in shares of Medtronic by 1,368.0% during the fourth quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after purchasing an additional 37,265 shares in the last quarter. PFG Advisors raised its holdings in Medtronic by 55.0% in the 1st quarter. PFG Advisors now owns 4,144 shares of the medical technology company’s stock valued at $372,000 after buying an additional 1,471 shares during the last quarter. Venturi Wealth Management LLC boosted its position in Medtronic by 9.5% during the 1st quarter. Venturi Wealth Management LLC now owns 6,982 shares of the medical technology company’s stock worth $627,000 after buying an additional 608 shares during the period. AE Wealth Management LLC lifted its stake in shares of Medtronic by 7.2% in the first quarter. AE Wealth Management LLC now owns 8,899 shares of the medical technology company’s stock worth $800,000 after acquiring an additional 597 shares during the period. Finally, Pinnacle Associates Ltd. boosted its holdings in Medtronic by 0.7% in the first quarter. Pinnacle Associates Ltd. now owns 121,244 shares of the medical technology company’s stock valued at $10,895,000 after acquiring an additional 815 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

Shares of NYSE MDT opened at $101.16 on Friday. The firm has a market capitalization of $129.76 billion, a P/E ratio of 27.87, a P/E/G ratio of 2.42 and a beta of 0.77. The firm’s 50-day moving average price is $95.04 and its 200-day moving average price is $90.88. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $102.59.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The business had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the company posted $1.26 EPS. The firm’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Jefferies Financial Group restated a “hold” rating and set a $110.00 price target on shares of Medtronic in a report on Wednesday. Stifel Nicolaus lifted their target price on shares of Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. JPMorgan Chase & Co. upped their price target on shares of Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Morgan Stanley increased their price target on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, UBS Group boosted their price objective on Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $109.72.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of the company’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director William R. Jellison bought 2,500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was purchased at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the completion of the acquisition, the director owned 5,000 shares in the company, valued at $461,850. This represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.